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The ‘big three’ killer diseases are malaria, human immunode-
ﬁciency virus (HIV)/AIDS, and tuberculosis (TB), which prob-
ably account together for >6 million deaths per year. In the
past 15 years, major sources of funding, including from the
UN’s Global Fund, have led to signiﬁcant progress in the ﬁght
against each one of these diseases (http://www.theglobalfund.
org/en/). However, recent reports and data are calling into
question an optimism that might have been too premature.
The access to and early use of effective antimalarial
treatment—the most effective antimalarial drugs being arte-
misinin-based combination therapies and the emerging
approach of intermittent preventive treatment—have been
key elements in the decline in global malaria incidence in the
past 10 years [1]. However, the emergence of artemisinin
resistance on the Cambodia–Thailand border is of great
concern, and represents a major threat in the ﬁght against
malaria [2]. In this issue, Wongsrichanalai and Sibley [3] review
the background of artemisinin resistance, its situation, espe-
cially in the Greater Mekong Sub-region, the difﬁculties in
deﬁning and measuring resistance to artemisinin-based com-
bination therapies, and the efforts needed to control and limit
the spread of resistant parasites. The other major issue in the
ﬁght against malaria involves antivector procedures such as
indoor residual spraying, the use of long-lasting insecti-
cide-treated bed-nets, and the destruction of larval breeding
sites. However, the effectiveness of these tools is now being
challenged by the emergence and growth of insecticide
resistance [4]. Anopheles mosquito vectors have an amazing
capacity to adapt. They rapidly develop resistance to insecti-
cides. Their behaviour can also change because of our lifestyle
changes. In response to the use of mosquito bed-nets during
the night, some Anopheles mosquitoes change their biting
hours, feeding earlier when people are not yet protected by a
net. Also, when exposed to insecticides, indoor mosquitoes
start changing their behaviour, biting outdoors and sometimes
feeding on animals [5]. In this issue, Sokhna et al. [6] review
factors jeopardizing vector control, including biological resis-
tance to insecticides and behavioural adaptation to the
insecticide-based vector control interventions. Together,
these emerging phenomena may compromise malaria control,
and the development of new vector control interventions
should be considered. In the future, drug and/or insecticide
resistance in a context of weakening of malaria control
programmes could lead to a dramatic resurgence of malaria
globally [7].
Over the past two decades, the re-emergence of TB in
industrialized countries has been linkedwith immigration, and, in
sub-Saharan Africa, with the HIV epidemic. Two major threats
have emerged, including the potential for Mycobacterium tuber-
culosis Beijing strains, which are now pandemic, to cause
outbreaks, and the rise of drug-resistant TB [8]. Basically, these
threats are connected, as the Beijing strain family is character-
ized by its potential to cause epidemics and its association with
drug resistance [9]. Several outbreaks of TB caused by
M. tuberculosis Beijing have been reported in crowded environ-
ments, such as homeless shelters and prisons, and, more
recently, in two schools in Marseille, France [9], and Milan, Italy
[10]. The high level of contagiousness of the source cases is a
major issue. The emergence of extensively drug-resistant TB
represents a critical challenge to public health authorities
globally. It has recently been brought up as a major concern in
TB control in South Africa [11]. In Europe, the problem has also
emerged in recent years. It has led to public and political issues,
as many cases in Europe have been diagnosed in foreign-born
patients and/or asylum seekers, coming from central/eastern
Europe or Asia [12,13]. In this issue, Borgdorff and Van
Soolingen [14] review the molecular epidemiology of TB, which,
over the last two decades, has contributed to its study and to an
understanding of its re-emergence. In addition, they also
examine the role of whole genome sequencing in answering
unresolved questions regarding the ﬁght against TB.
Finally, in this issue, Bozicevic et al. [15] present the trends of
the HIV epidemic in Europe. They describe an increase in the
numbers of reported HIV cases in some countries of western,
central and, particularly, of eastern Europe, where TB–HIV
co-infection is becoming an important issue. Importantly, HIV
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transmission inmenwho have sexwithmen is increasing inmany
European countries. This trend has also been reported outside
of Europe, such as recently in China [16]. Interestingly, several
European countries have described recent increases in the
incidence of several sexually transmitted infections, particularly
among men who have sex with men [17]. These data raise
questions about prevention, and particularly about communi-
cation strategies regarding the preventive interventions for HIV.
Sexually transmitted bacterial rectal infections are associated
with a higher risk of being infected with HIV [18]. Screening for
rectal sexually transmitted diseases and targeting populations
for risk reduction-speciﬁc counselling is critical. Other preven-
tion strategies might also emerge. Also, rectal microbicides,
such as antiretroviral gels, also referred to as topical pre-expo-
sure prophylaxis, are being studied and developed to prevent
new HIV infections [19].
In conclusion, the ﬁght against the big three killers is still
ongoing, and continuing work on implementing new weapons/
strategies is critical.
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